Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Advances in sickle cell therapies in the hydroxyurea era.

Field JJ, Nathan DG.

Mol Med. 2014 Dec 16;20 Suppl 1:S37-42. doi: 10.2119/molmed.2014.00187. Review.

2.

Cellular therapy for sickle cell disease.

Abraham A, Jacobsohn DA, Bollard CM.

Cytotherapy. 2016 Nov;18(11):1360-1369. doi: 10.1016/j.jcyt.2016.06.011. Epub 2016 Jul 14. Review.

3.

Treatment Options for Sickle Cell Disease.

Meier ER.

Pediatr Clin North Am. 2018 Jun;65(3):427-443. doi: 10.1016/j.pcl.2018.01.005. Review.

PMID:
29803275
4.

Therapeutic advances in sickle cell disease in the last decade.

Shet AS, Thein SL.

Indian J Med Res. 2017 Jun;145(6):708-712. doi: 10.4103/ijmr.IJMR_1153_17. No abstract available.

5.

Sickle Cell Disease: A Brief Update.

Azar S, Wong TE.

Med Clin North Am. 2017 Mar;101(2):375-393. doi: 10.1016/j.mcna.2016.09.009. Epub 2016 Dec 14. Review.

PMID:
28189177
6.

Hydroxyurea for children with sickle cell disease.

Heeney MM, Ware RE.

Pediatr Clin North Am. 2008 Apr;55(2):483-501, x. doi: 10.1016/j.pcl.2008.02.003. Review.

PMID:
18381097
7.

Hydroxyurea for children with sickle cell disease.

Heeney MM, Ware RE.

Hematol Oncol Clin North Am. 2010 Feb;24(1):199-214. doi: 10.1016/j.hoc.2009.11.002. Review.

8.

The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.

Kassim AA, DeBaun MR.

Expert Opin Pharmacother. 2014 Feb;15(3):325-36. doi: 10.1517/14656566.2014.868435. Epub 2014 Jan 7. Review.

PMID:
24392871
9.

Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.

Tantawy AA, Adly AA, Ismail EA, Darwish YW, Ali Zedan M.

Blood Cells Mol Dis. 2014 Dec;53(4):189-93. doi: 10.1016/j.bcmd.2014.07.003. Epub 2014 Jul 25.

PMID:
25065856
10.

Investigational agents for sickle cell disease.

Okpala I.

Expert Opin Investig Drugs. 2006 Aug;15(8):833-42. Review.

PMID:
16859388
11.

Fertility challenges for women with sickle cell disease.

Ghafuri DL, Stimpson SJ, Day ME, James A, DeBaun MR, Sharma D.

Expert Rev Hematol. 2017 Oct;10(10):891-901. doi: 10.1080/17474086.2017.1367279. Epub 2017 Sep 11. Review.

PMID:
28891355
12.

Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies.

Bauer DE, Brendel C, Fitzhugh CD.

Blood Cells Mol Dis. 2017 Sep;67:155-168. doi: 10.1016/j.bcmd.2017.08.014. Epub 2017 Sep 1. Review.

PMID:
28893518
13.

Clinical Features of β-Thalassemia and Sickle Cell Disease.

McGann PT, Nero AC, Ware RE.

Adv Exp Med Biol. 2017;1013:1-26. doi: 10.1007/978-1-4939-7299-9_1.

PMID:
29127675
14.

[How I treat ... sickle cell anemia: current therapies].

Rezaei Kalantari H.

Rev Med Liege. 2001 Oct;56(10):671-5. Review. French.

PMID:
11765575
15.

Sickle cell disease.

Ware RE, de Montalembert M, Tshilolo L, Abboud MR.

Lancet. 2017 Jul 15;390(10091):311-323. doi: 10.1016/S0140-6736(17)30193-9. Epub 2017 Feb 1. Review.

PMID:
28159390
16.

Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease?

Field JJ.

Hematology Am Soc Hematol Educ Program. 2015;2015:426-32. doi: 10.1182/asheducation-2015.1.426.

PMID:
26637753
17.

Smoothing the crescent curve: sickle cell disease.

Talano JA, Cairo MS.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):468-74. doi: 10.1182/asheducation-2014.1.468. Epub 2014 Nov 18. Review.

PMID:
25696896
18.

Haematopoietic stem cell transplantation for sickle cell disease - current practice and new approaches.

Arnold SD, Bhatia M, Horan J, Krishnamurti L.

Br J Haematol. 2016 Aug;174(4):515-25. doi: 10.1111/bjh.14167. Epub 2016 Jun 2. Review.

PMID:
27255787
19.

Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J.

JAMA. 2014 Sep 10;312(10):1033-48. doi: 10.1001/jama.2014.10517. Review. Erratum in: JAMA. 2014 Nov 12;312(18):1932. JAMA. 2015 Feb 17;313(7):729.

PMID:
25203083
20.

Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.

Adly AA, Ismail EA, Andrawes NG, Mahmoud MM, Eladawy R.

Cytokine. 2016 Mar;79:52-8. doi: 10.1016/j.cyto.2015.12.022. Epub 2016 Jan 5.

PMID:
26765484

Supplemental Content

Support Center